Answers are grounded in this paper and cite their sources.
In response to the COVID-19 pandemic, local SARS-CoV-2 nanopore sequencing capacity was established at Irrua Specialist Teaching Hospital (ISTH), a Lassa fever reference centre based in Edo State, Nigeria. This was enabled through training of local staff in Nigeria and Guinea in both laboratory and bioinformatic SARS-CoV-2 sequencing protocols. Between March 2020 and December 2023, the laboratory at ISTH conducted 29,643 diagnostic tests for SARS-CoV-2, of which 4,575 (15.4%) were positive. Between April and December 2022, 410 SARS-CoV-2 positive samples were selected and retrospectively sequenced in 19 runs. From these, 213 near-complete (> 93%) viral genomes were generated and submitted to GISAID. Phylogenetic and phylogeographic analyses supported that Nigeria served simultaneously as a source and recipient of SARS-CoV-2 lineages, driving global spread of the AY.36 Delta variant and receiving Omicron sublineages (BA.1.1 and BQ.1) from North America and Europe. Here we show that a pre-existing long-term laboratory capacity development program for Lassa virus, a high-risk pathogen, facilitated the successful integration of novel workflows for a new emerging pathogen.
No takes yet. Share an insight, caveat, or question.
Erameh et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: